# Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

> **NCT02339922** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Washington** · enrollment: 33 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Small Lymphocytic Lymphoma
- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Ixazomib Citrate
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT02339922
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05-19
- **Primary completion:** 2024-12-30
- **Final completion:** 2031-01-06
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02339922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02339922, "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02339922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*